Who is sponsoring NCT02558894?

NCT02558894 is sponsored by AstraZeneca.

What drugs are being tested in NCT02558894?

Interventions in NCT02558894: MEDI4736 monotherapy, tremelimumab+MEDI4736.

What condition does NCT02558894 study?

NCT02558894 studies Metastatic Pancreatic Ductal Adenocarcinoma.

Is NCT02558894 still recruiting?

NCT02558894 is currently completed. Last updated 2 August 2018.

Are results published for NCT02558894?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-08-02 · How we verify

NCT02558894

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

Completed Phase 2 Results posted Last updated 2 August 2018

What this trial tests

Phase 2 trial testing MEDI4736 monotherapy in Metastatic Pancreatic Ductal Adenocarcinoma in 65 participants. Completed in 15 June 2017.

Timeline

16 November 2015

Primary endpoint
15 June 2017

15 June 2017

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	65
Start date	16 November 2015
Primary completion	15 June 2017
Estimated completion	15 June 2017
Sites	21 locations across Netherlands, Germany, South Korea, Canada, United States, Spain

Drugs / interventions tested

MEDI4736 monotherapy — full drug profile →
tremelimumab+MEDI4736 — full drug profile →

Conditions studied

Metastatic Pancreatic Ductal Adenocarcinoma — all drugs for Metastatic Pancreatic Ductal Adenocarcinoma →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Metastatic Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Objective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Primary · From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)

ORR was defined as the percentage of patients with at least one visit response of confirmed complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have had reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters. A confirmed response meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging, preferably at the next regularly schedul

Confirmed responses only

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	3.1	0.08 – 16.22
Durvalumab (MEDI4736) Monotherapy	0	0 – 10.58

Confirmed and unconfirmed responses

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	3.1	0.08 – 16.22
Durvalumab (MEDI4736) Monotherapy	6.1	0.74 – 20.23

Progression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.1 Secondary · From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)

PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. Results are reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1.5	1.2 – 1.5
Durvalumab (MEDI4736) Monotherapy	1.5	1.3 – 1.5

PFS Rate at 3 Months and at 6 Months Secondary · From date of first infusion until confirmed disease progression or death (up to 3 months and 6 months)

PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. PFS rates were calculated using Kaplan-Meier estimates of the cumulative probability of PFS. The PFS rate at 3 months and 6 months was equivalent to the percentage of patients with PFS after 3 months and 6 months, respectively.

PFS rate at 3 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	9.4	2.4 – 22.3
Durvalumab (MEDI4736) Monotherapy	10.9	3.0 – 24.7

PFS rate at 6 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	9.4	2.4 – 22.3
Durvalumab (MEDI4736) Monotherapy	3.6	0.3 – 15.4

Overall Survival (OS) Secondary · From date of first infusion until death (up to approximately 18 months for the data analysis cut-off)

OS was defined as the time from the date of randomisation until death due to any cause. Results are reported as median OS, calculated using the Kaplan-Meier technique.

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	3.1	2.2 – 6.1
Durvalumab (MEDI4736) Monotherapy	3.6	2.7 – 6.1

Survival Status, Presented as OS Rate, at 6 Months and at 12 Months Secondary · From date of first infusion until death (up to 6 months and 12 months)

OS was defined as the time from the date of randomisation until death due to any cause. OS rates were calculated using Kaplan-Meier estimates of the cumulative probability of survival at each indicated time period. The OS rate at 6 months and 12 months was equivalent to the percentage of patients with OS after 6 months and 12 months, respectively.

Survival rate at 6 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	36.2	20.0 – 52.7
Durvalumab (MEDI4736) Monotherapy	34.9	19.2 – 51.1

Survival rate at 12 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	8.8	1.8 – 22.8
Durvalumab (MEDI4736) Monotherapy	6.3	1.1 – 18.4

Best Objective Response (BoR) Using Investigator Assessments According to RECIST 1.1 Secondary · From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)

BoR was calculated based on the overall visit responses from each RECIST assessment. It was the best response a patient had following date of first dosing but prior to starting any subsequent cancer therapy and prior to RECIST progression or last evaluable assessment in absence of RECIST progression. Categorisation of BoR was based on RECIST using the following response categories: CR and PR for status of 'Response'; Stable Disease (SD) ≥6 weeks, Progressive Disease (PD) and Not Evaluable (NE) for status of 'Non-response'. SD was defined as neither sufficient shrinkage to qualify for PR nor su

Response: Total

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1
Durvalumab (MEDI4736) Monotherapy	0

Response: CR

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	0

Response: PR

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1
Durvalumab (MEDI4736) Monotherapy	0

Non-response: Total

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	31
Durvalumab (MEDI4736) Monotherapy	33

Non-response: Stable disease ≥6 weeks

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	5
Durvalumab (MEDI4736) Monotherapy	7

Non-response: Progression of disease

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	26
Durvalumab (MEDI4736) Monotherapy	25

Non-response: Not evaluable

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	1

Disease Control Rate (DCR) Using Investigator Assessments According to RECIST 1.1 Secondary · From date of first infusion until confirmed disease progression or death (up to 3 months, 6 months and 12 months)

DCR at 3 months was defined as the percentage of patients who have a BoR of CR or PR in the first 3 months or who have demonstrated SD for a minimum interval of 13 weeks following the start of treatment. DCR at 6 months was defined as the percentage of patients who have a BoR of CR or PR in the first 6 months or who have demonstrated SD for a minimum interval of 26 weeks following the start of treatment. DCR at 12 months was defined as the percentage of patients who have a BoR of CR or PR in the first 12 months or who have demonstrated SD for a minimum interval of 52 weeks following the start

At 3 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	9.4	1.98 – 25.02
Durvalumab (MEDI4736) Monotherapy	6.1	0.74 – 20.23

At 6 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	6.3	0.77 – 20.81
Durvalumab (MEDI4736) Monotherapy	0	0.00 – 10.58

At 12 months

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	3.1	0.08 – 16.22
Durvalumab (MEDI4736) Monotherapy	0	0.00 – 10.58

Pharmacokinetics (PK) of Durvalumab (MEDI4736) Secondary · Blood samples were collected pre-dose on Day 1 (Week 0), Week 4, Week 12 and Week 24, post-dose on Day 1, Week 12 and Week 24, and additionally at 3 months after the last dose (follow-up).

To evaluate PK, blood samples were collected pre- and post-dose and durvalumab (MEDI4736) concentrations in serum were determined. On Day 1 of Cycles 1, 4 and 7 (Weeks 0, 12 and 24), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of durvalumab and within 10 minutes of end of infusion of tremelimumab \[for patients receiving durvalumab plus tremelimumab\]). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3

Cycle 1, Day 1, pre-infusion (Day 1)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	217.338	± 345.4913

Cycle 1, Day 1, post-infusion (Day 1)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	566.078	± 151.4199
Durvalumab (MEDI4736) Monotherapy	562.218	± 152.3811

Cycle 2, Day 1, pre-infusion (Day 29)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	100.417	± 39.7229
Durvalumab (MEDI4736) Monotherapy	98.668	± 36.5072

Cycle 4, Day 1, pre-infusion (Day 85)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	236.205	± 98.8964
Durvalumab (MEDI4736) Monotherapy	228.450	± 36.8395

Cycle 4, Day 1, post-infusion (Day 85)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	825.818	± 322.8247
Durvalumab (MEDI4736) Monotherapy	760.456	± 100.6974

Cycle 7, Day 1, pre-infusion (Day 169)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	166.736	± 47.3872
Durvalumab (MEDI4736) Monotherapy	152.706	± NA

Cycle 7, Day 1, post-infusion (Day169)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	918.270	± 98.4286
Durvalumab (MEDI4736) Monotherapy	825.578	± NA

3-month follow-up

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	38.456	± NA
Durvalumab (MEDI4736) Monotherapy	19.684	± 20.2664

PK of Tremelimumab Secondary · Blood samples were collected pre-dose on Day 1 (Week 0), Week 4 and Week 12, post-dose on Day 1 and Week 12, and additionally at 3 months after the last dose (follow-up).

To evaluate PK, blood samples were collected pre- and post-dose and tremelimumab concentrations in serum were determined. On Day 1 of Cycles 1 and 4 (Weeks 0 and 12), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of tremelimumab). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for tremelimumab was relative to the respective last dose. Results are reported as mean pre- or post-do

Cycle 1, Day 1, pre-infusion (Day 1)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	13.114	± 11.7182

Cycle 1, Day 1, post-infusion (Day 1)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	24.477	± 6.3516

Cycle 2, Day 1, pre-infusion (Day 29)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	4.880	± 2.2623

Cycle 4, Day 1, pre-infusion (Day 85)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	8.753	± 4.9962

Cycle 4, Day 1, post-infusion (Day 85)

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	21.150	± 5.8997

Presence of Antidrug Antibodies (ADAs) for Durvalumab (MEDI4736) Secondary · Immunogenicity samples were collected on Day 1 (Week 0), Week 4, Week 12 and Week 24, and additionally at 3 months and 6 months after the last dose (follow-up).

ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positi

ADA prevalence

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1
Durvalumab (MEDI4736) Monotherapy	5

ADA incidence

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	3

ADA pos post-baseline and pos at baseline

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	0

ADA pos post-baseline and not detected at baseline

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	3

ADA not detected post-baseline and pos at baseline

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1
Durvalumab (MEDI4736) Monotherapy	2

Treatment-boosted ADA

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	0

Persistent positive

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	3

Transient positive

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0
Durvalumab (MEDI4736) Monotherapy	0

Presence of ADAs for Tremelimumab Secondary · Immunogenicity samples were collected on Day 1 (Week 0), Week 4 and Week 12, and additionally at 3 months and 6 months after the last dose (follow-up).

ADA prevalence

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	2

ADA incidence

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0

ADA pos post-baseline and pos at baseline

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1

ADA pos post-baseline and not detected at baseline

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0

ADA not detected post-baseline and pos at baseline

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1

Treatment-boosted ADA

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0

Persistent positive

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	0

Transient positive

Group	Value	95% CI
Durvalumab (MEDI4736) Plus Tremelimumab	1

Adverse events — posted to ClinicalTrials.gov

Time frame: Treatment-emergent adverse event (TEAE) data is reported for the treatment period (up to 12 months) + follow-up (up to 90 days). Overall timeframe: up to approximately 15 months.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Durvalumab (MEDI4736) Plus Tremelimumab

Serious: 11/32 (34%)

Deaths: 19/32

Durvalumab (MEDI4736) Monotherapy

Serious: 9/32 (28%)

Deaths: 16/32

Serious adverse events (25 terms)

Reaction	System	Durvalumab (MEDI4736) Plus…	Durvalumab (MEDI4736) Mono…
Diarrhoea	Gastrointestinal disorders	—	—
Ascites	Gastrointestinal disorders	—	—
Pyrexia	General disorders	—	—
Cholangitis	Hepatobiliary disorders	—	—
Acute kidney injury	Renal and urinary disorders	—	—
Abdominal distension	Gastrointestinal disorders	—	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—	—
Haematemesis	Gastrointestinal disorders	—	—
Haematochezia	Gastrointestinal disorders	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—
Large intestine perforation	Gastrointestinal disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Asthenia	General disorders	—	—
Fatigue	General disorders	—	—
Autoimmune hepatitis	Hepatobiliary disorders	—	—
Bacteraemia	Infections and infestations	—	—
Enterococcal sepsis	Infections and infestations	—	—
Infection	Infections and infestations	—	—
Sepsis	Infections and infestations	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—
Myositis	Musculoskeletal and connective tissue disorders	—	—
Rheumatoid arthritis	Musculoskeletal and connective tissue disorders	—	—
Endometrial cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—
Embolism	Vascular disorders	—	—

Other adverse events (40 terms — click to expand)

Reaction	System	Durvalumab (MEDI4736) Plus…	Durvalumab (MEDI4736) Mono…
Fatigue	General disorders	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Dyspepsia	Gastrointestinal disorders	—	—
Pyrexia	General disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Hypothyroidism	Endocrine disorders	—	—
Asthenia	General disorders	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—
Abdominal pain	Gastrointestinal disorders	—	—
Ascites	Gastrointestinal disorders	—	—
Feeling cold	General disorders	—	—
Oedema peripheral	General disorders	—	—
Hypophagia	Metabolism and nutrition disorders	—	—
Cancer pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Insomnia	Psychiatric disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Rash	Skin and subcutaneous tissue disorders	—	—
Deep vein thrombosis	Vascular disorders	—	—
Thyroiditis	Endocrine disorders	—	—
Dry mouth	Gastrointestinal disorders	—	—
Flatulence	Gastrointestinal disorders	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—
Cholangitis	Hepatobiliary disorders	—	—
Gingivitis	Infections and infestations	—	—
Weight decreased	Investigations	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—
Dizziness	Nervous system disorders	—	—
Headache	Nervous system disorders	—	—
Anxiety	Psychiatric disorders	—	—
Confusional state	Psychiatric disorders	—	—
Dry skin	Skin and subcutaneous tissue disorders	—	—
Nail ridging	Skin and subcutaneous tissue disorders	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—
Hypotension	Vascular disorders	—	—

Most-reported serious reactions: Diarrhoea, Ascites, Pyrexia, Cholangitis, Acute kidney injury, Abdominal distension, Gastrointestinal haemorrhage, Haematemesis.

Data from ClinicalTrials.gov NCT02558894 adverse events section.

Sponsor's own description

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, et al · · 2022 · cited 1018× · PMID 35062949 · DOI 10.1186/s12943-021-01489-2
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
O'Reilly EM, Oh DY, Dhani N, Renouf DJ, et al · · 2019 · cited 565× · PMID 31318392 · DOI 10.1001/jamaoncol.2019.1588
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Adamska A, Domenichini A, Falasca M. · · 2017 · cited 429× · PMID 28640192 · DOI 10.3390/ijms18071338
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.
Wang S, Zheng Y, Yang F, Zhu L, et al · · 2021 · cited 252× · PMID 34219130 · DOI 10.1038/s41392-021-00659-4
An update on treatment options for pancreatic adenocarcinoma.
Lambert A, Schwarz L, Borbath I, Henry A, et al · · 2019 · cited 155× · PMID 31598142 · DOI 10.1177/1758835919875568
Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA, Yarchoan M, Lee V, Laheru DA, et al · · 2017 · cited 136× · PMID 28373364 · DOI 10.1158/1078-0432.ccr-16-2318
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer.
Saka D, Gökalp M, Piyade B, Cevik NC, et al · · 2020 · cited 106× · PMID 32823814 · DOI 10.3390/cancers12082274

Verify or expand the search:

Other trials of MEDI4736 monotherapy

Trials testing the same drug.

NCT02527434 — Study of Tremelimumab in Patients With Advanced Solid Tumors · Phase 2 · completed

Other recruiting trials for Metastatic Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

NCT06904378 — ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
NCT07214298 — Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
NCT07089940 — OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT06989437 — A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif · Phase 2, PHASE3 · recruiting
NCT07096362 — Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma · Phase 2 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02558894 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 2 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02558894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing